Company Analysis
Sign in

Arvinas, Inc. (ARVN)

Nasdaq: ARVN · Pharmaceutical Preparations · New Haven, CT · filing with the SEC since 2015
Full chart Alerts Compare
Grade5.7
◀ Past 6.6● Present 6.0▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

60 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Arvinas, Inc.’s names, not what it holds today.

Patents granted
60
60 utility, 1976 to Dec 31, 2025
Granted in 2025
13
Against 19 in 2024 and 4 in 2023
Applications published
127
21 of them in 2025
Names they are printed under
4
a subsidiary, its own name
By yearGrantedApplications published
'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals27
Organic fine chemistry23
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Arvinas Operations, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
93 published
Arvinas Operations, Inc. a subsidiary
US, as the owner printed on each patent
58 granted
8 published
Arvinas, Inc. its own name
named as the applicant on its applications, in US
0 granted
25 published
Arvinas, Inc. its own name
US, as the owner printed on each patent
2 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,496,301Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophyPharmaceuticalsArvinas Operations, Inc.
Nov 18, 202512,473,294Selective modulators of mutant LRRK2 proteolysis and associated methods of usePharmaceuticalsArvinas Operations, Inc.
Oct 21, 202512,448,399Cereblon-based KRAS degrading PROTACs and uses related theretoPharmaceuticalsArvinas Operations, Inc.
Oct 14, 202512,441,708Cereblon ligands and bifunctional compounds comprising the sameOrganic fine chemistryArvinas Operations, Inc.
Sep 30, 202512,427,144Compounds and methods for the targeted degradation of androgen receptorPharmaceuticalsArvinas Operations, Inc.
Sep 23, 202512,419,960Compounds and methods for the targeted degradation of androgen receptor and associated methods of useOrganic fine chemistryArvinas Operations, Inc.
May 27, 202512,312,316Compounds and methods for the targeted degradation of androgen receptorOrganic fine chemistryArvinas Operations, Inc.
May 27, 202512,310,975Modulators of BCL6 proteolysis and associated methods of usePharmaceuticalsArvinas Operations, Inc.
Apr 29, 202512,286,419Methods of manufacturing a bifunctional compoundOrganic fine chemistryArvinas Operations, Inc.
Apr 15, 202512,275,716Modulators of estrogen receptor proteolysis and associated methods of useOrganic fine chemistryArvinas Operations, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360219CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAMEPharmaceuticalsArvinas Operations, Inc.
Oct 30, 20252025/0332110PHARMACEUTICAL FORMULATIONS OF AN ANDROGEN RECEPTOR-TARGETING PROTEIN DEGRADERPharmaceuticalsArvinas Operations, Inc.
Oct 23, 20252025/0326740METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUNDOrganic fine chemistryArvinas Operations, Inc.
Oct 16, 20252025/0320195TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERSPharmaceuticalsArvinas Operations, Inc.
Oct 9, 20252025/0313547CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAMEOrganic fine chemistryArvinas Operations, Inc.
Sep 11, 20252025/0282750METHODS OF MANUFACTURING AN ANDROGEN RECEPTOR PROTEIN DEGRADEROrganic fine chemistryArvinas Operations, Inc.
Aug 7, 20252025/0248999BAVDEGALUTAMIDE AND COMBINATIONS THEREOF FOR USE IN TREATING PROSTATE CANCERPharmaceuticalsArvinas Operations, Inc.
Jul 24, 20252025/0236612RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USEOrganic fine chemistryArvinas Operations, Inc.
Jul 17, 20252025/0228952BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2)PharmaceuticalsArvinas Operations, Inc.
Jul 17, 20252025/0228944COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINSOrganic fine chemistryArvinas Operations, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 26 · Organic fine chemistry 15.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARVN · research, not advice